De novo pyrimidine synthesis controls germinal center B cell and plasma cell fates and systemic autoimmunity
Cell Reports · 2026-07 · 45 (7) · 117587
DOI: 10.1016/j.celrep.2026.117587 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2026-07. Verfasst von Julia L Weber und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA 19107, USA; Department of Cell and Biological Systems (forme…. Hauptthemen laut MEDLINE: Pyrimidines, Plasma Cells, Germinal Center, Autoimmunity. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, National Cancer Center.
Abstract (Originalsprache)
Whether and how pyrimidine metabolites promote systemic autoimmunity is unknown. Here, metabolomics and 15N-amide glutamine tracing show enhanced flux through de novo pyrimidine synthesis in systemic lupus erythematosus (SLE)-prone B cells. Temporal inhibition of pyrimidine synthesis dampens SLE-prone but not foreign antigen-specific germinal center (GC), plasma cell (PC), and antibody responses. Uridine monophosphate synthase (UMPS) conditional deletion, however, reveals a B cell-intrinsic requirement of de novo pyrimidine synthesis in foreign antigen-driven and SLE-prone GC, PC, and antibody responses and kidney immune complex deposition. Metabolomics, mitochondrial stress test, metabolic flow cytometry, glycolytic rate assay, and RNA sequencing highlight the importance of pyrimidine synthesis in promoting aerobic glycolysis and oxidative phosphorylation in SLE-prone B cells. De novo pyrimidine synthesis helps SLE-prone B cells maintain heightened metabolic state and expression of metabolic regulator, cMYC. Mechanistically, mTORC1 and S6K1 downstream of TLR7 and CD40 signaling in B cells promote pyrimidine synthesis by activating CAD, a rate-limiting enzyme of this pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA 19107, USA; Department of Cell and Biological Systems (formerly known as Microbiology and Immunology), Pennsylvania State Universi…
- Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
- Department of Cell and Biological Systems (formerly known as Microbiology and Immunology), Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
- The Wistar Institute, Philadelphia, PA 19104, USA.
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- National Cancer Center
- National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases
Zitieren
APA
Weber, J. L., Bui, T., Nuon, K., Fike, A. J., Crocker, S. M., Bricker, K. N., Maharjan, A., Zhang, W., Goldman, A. R., Chodisetti, S. B., & Rahman, Z. S. M. (2026). De novo pyrimidine synthesis controls germinal center B cell and plasma cell fates and systemic autoimmunity. Cell Reports, 45(7), 117587. https://doi.org/10.1016/j.celrep.2026.117587
Vancouver
Weber JL, Bui T, Nuon K, Fike AJ, Crocker SM, Bricker KN, et al. De novo pyrimidine synthesis controls germinal center B cell and plasma cell fates and systemic autoimmunity. Cell Reports. 2026;45(7):117587. doi:10.1016/j.celrep.2026.117587
BibTeX
@article{Weber2026,
author = {Weber, Julia L and Bui, Tien and Nuon, Keomonyroth and Fike, Adam J and Crocker, Sophia M and Bricker, Kristen N and Maharjan, Anju and Zhang, Wujuan and Goldman, Aaron R and Chodisetti, Sathi Babu and Rahman, Ziaur S M},
title = {De novo pyrimidine synthesis controls germinal center B cell and plasma cell fates and systemic autoimmunity},
journal = {Cell Reports},
year = {2026},
volume = {45},
number = {7},
pages = {117587},
doi = {10.1016/j.celrep.2026.117587}
}
EUVIMED